Ireland - English - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - heparin sodium ; sodium chloride; disodium phosphate dodecahydrate; citric acid monohydrate - solution for infusion - 1000 iu/l + 0.9 percent weight/volume - heparin group; heparin

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - heparin sodium, quantity: 2000 iu/l - injection, solution - excipient ingredients: water for injections; sodium chloride; citric acid monohydrate; dibasic sodium phosphate dodecahydrate - indications as at 11 july 2003: heparin sodium in 0.9% sodium chloride intravenous infusion is indicated as an anticoagulant in extracorporeal circulation, dialysis procedures, and as an aid in the maintenance of catheter patency.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - heparin sodium, quantity: 1000 iu/l - injection, solution - excipient ingredients: sodium chloride; citric acid monohydrate; dibasic sodium phosphate dodecahydrate; water for injections - indications as at 11 july 2003: heparin sodium in 0.9% sodium chloride intravenous infusion is indicated as an anticoagulant in extracorporeal circulation, dialysis procedures, and as an aid in the maintenance of catheter patency.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 25000 iu/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - heparin is indicated for the prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism and occlusive vascular disease. it is also used to prevent thromboembolic complications arising from cardiac and vascular surgery, frostbite, dialysis and other perfusion procedures. heparin is also used as an anticoagulant in blood transfusions

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 1000 iu/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - heparin is indicated for the prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism and occlusive vascular disease. it is also used to prevent thromboembolic complications arising from cardiac and vascular surgery, frostbite, dialysis and other perfusion procedures. heparin is also used as an anticoagulant in blood transfusions

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 5000 iu/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - heparin is indicated for the prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism and occlusive vascular disease. it is also used to prevent thromboembolic complications arising from cardiac and vascular surgery, frostbite, dialysis and other perfusion procedures. heparin is also used as an anticoagulant in blood transfusions

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 150 mg - injection, solution - excipient ingredients: nitrogen; water for injections - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 120 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 80 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).